Alan P. Kozikowski

机构：Hadassah Medical Center, Chembio (United States), MBio Diagnostics (United States), Molecular Theranostics (United States) · ORCID：0000-0003-4795-5368

发表论文 890 篇 · 总被引 29305 次 · h-index 85

代表论文

• Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells (2019 · Scientific Reports · 被引 118)
• A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019) (2019 · Expert Opinion on Therapeutic Patents · 被引 91)
• Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor (2020 · ACS Medicinal Chemistry Letters · 被引 85)
• Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models (2019 · Journal of Medicinal Chemistry · 被引 85)
• Correction: Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR–mediated DNA Damage Response (2019 · Clinical Cancer Research · 被引 75)
• HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice (2020 · Experimental Neurology · 被引 63)